Two-way arginine transport in human endothelial cells:
TNF-
stimulation is restricted to system y+
Roberto
Sala1,
Bianca Maria
Rotoli1,
Emanuela
Colla1,
Rossana
Visigalli1,
Alessandro
Parolari2,
Ovidio
Bussolati1,
Gian C.
Gazzola1, and
Valeria
Dall'Asta1
1 Dipartimento di Medicina Sperimentale, Sezione di
Patologia Generale e Clinica, Università degli Studi di
Parma, 43100 Parma; and 2 Cattedra di Cardiochirurgia,
Centro Cardiologico Monzino Istituto di Ricovero e Cura a Carattere
Scientifico, Università degli Studi di Milano, 20122 Milan, Italy
 |
ABSTRACT |
Human
umbilical vein endothelial cells transport arginine through two
Na+-independent systems. System y+L is
insensitive to N-ethylmaleimide (NEM), inhibited by
L-leucine in the presence of Na+, and referable
to the expression of SLC7A6/y+LAT2,
SLC7A7/y+LAT1, and SLC3A2/4F2hc. System y+ is
referable to the expression of SLC7A1/CAT1 and SLC7A2/CAT2B. Tumor
necrosis factor-
(TNF-
) and bacterial lipopolysaccharide induce a
transient stimulation of arginine influx and efflux through system
y+. Increased expression of SLC7A2/CAT2B is detectable from
3 h of treatment, while SLC7A1 expression is inhibited at later
times of incubation. System y+L activity and expression
remain unaltered. Nitric oxide synthase type 2 mRNA is not detected in
the absence or presence of TNF-
, while the latter condition lowers
nitric oxide synthase type 3 expression at the mRNA and the protein
level. Nitrite accumulation is comparable in cytokine-treated and
control cells up to 48 h of treatment. It is concluded that
modulation of endothelial arginine transport by TNF-
or
lipopolysaccharide occurs exclusively through changes in CAT2B and CAT1
expression and is dissociated from stimulation of nitric oxide production.
system y+L; cationic amino acid transporters; SLC7A
genes; lipopolysaccharide; nitric oxide
 |
INTRODUCTION |
NITRIC OXIDE (NO)
produced by endothelial cells is an important regulator of vascular
tone, cell adhesion, and vascular permeability (2, 34).
Depending on concentration, NO can have beneficial and protective
effects or exert deleterious actions through enzyme inhibition, DNA
damage promotion, induction of lipid peroxidation, or antioxidant
depletion (21). Under physiological conditions, low levels
of endothelial NO are synthesized from L-arginine through a
calcium/calmodulin-dependent NO synthase [NO synthase type III (NOS3)].
The possible involvement of modifications of arginine transport in the
regulation of endothelial NO synthesis has been investigated in
short-term and chronic experiments. Short-term stimulation of arginine
transport, obtained with shear stress (41), treatment with
A2-purinoceptor agonists (43), or incubation
in the presence of bradykinin (4), is followed by enhanced
NO production. Less clear results have been obtained when arginine
uptake is stimulated chronically. Several reports described a slowly
ensuing stimulation of arginine transport by lipopolysaccharide (LPS)
and tumor necrosis factor-
(TNF-
) in porcine and human
endothelium (7, 28, 38). Stimulation of arginine transport
by proinflammatory cytokines has been confirmed in porcine endothelial
cells by other authors (15), who, however, found no
correlation between the increased uptake of the cationic amino acid and
enhanced production of NO (16). In contrast, in a study
performed in human umbilical vein endothelial cells (HUVECs), a
correlation was found between NO production and arginine transport
(23).
Most of those investigations were based on previous characterization
studies that attributed endothelial transport of arginine to a single
Na+-independent pathway identified with the ubiquitous
system y+ (6, 31). However, it is now accepted
that at least four distinct transport pathways, systems y+,
y+L, b0,+, and B0,+, cooperate for
arginine transport in mammalian cells (14, 37). Indeed,
recent results from our group have demonstrated that, in human
fibroblasts, arginine transport, once attributed solely to system
y+, is due to the additive operation of systems
y+ and y+L (11). Although both
systems are Na+-independent exchange mechanisms for
cationic amino acids, they present clear-cut differences (see Refs.
14 and 37 for review). System y+ is
membrane potential dependent and interacts with neutral amino acids
with a very low affinity. Its activity is referable to the cationic
amino acid transporter (CAT) family of monomeric transporters, encoded
by SLC7A genes. The ubiquitous CAT1, encoded by SLC7A1, and the two
transporters CAT2A and CAT2B, derived from the alternative splicing of
the SLC7A2 transcript, are the best characterized members of the family
(8, 30). Conversely, system y+L is not
sensitive to membrane potential and exhibits a high-affinity, strictly
Na+-dependent interaction with neutral amino acids, such as
leucine. System y+L is a member of the recently
characterized group of the heterodimeric amino acid transporters (see
Ref. 45 for review), formed by a light and a heavy
subunit. In the case of system y+L, the heavy subunit is
4F2hc/CD98, the product of the SLC3A2 gene, while two alternative light
chains have been characterized, y+LAT1 (encoded by SLC7A7)
and y+LAT2 (encoded by SLC7A6).
In this report, we document the presence of system y+L in
human endothelium and describe the effects of LPS and TNF-
on the discriminated transport mechanisms as well as on the expression of the
respective genes. The results point to system y+ as the
sole target of these proinflammatory compounds and exclude a direct
correlation between transport changes and nitrite production.
 |
MATERIALS AND METHODS |
Cell culture and experimental treatment.
Cultures of HUVECs were obtained from three distinct cords according to
the method of Jaffe et al. (24), with minor modifications as described previously (6). Cells were routinely grown in collagen-coated 10-cm-diameter dishes in medium 199 (M199), with glutamine concentration raised to 2 mM. The culture medium was supplemented with 40% fetal bovine serum (FBS), 20 µg/ml endothelial cell growth supplement, and 15 U/ml heparin. The conditions of culture
were as follows: pH 7.4, 5% CO2 in air, and 37°C.
Cultures consisted of homogeneous endothelial populations, as
determined by typical cobblestone morphology and positivity to von
Willebrand's factor and CD31/platelet endothelial cell adhesion
molecule-1 antigens (39). Culture medium was always
renewed 24 h before the experiment.
Human bone marrow stromal cells (a gift of Dr. Nicola Giuliani, Dept.
of Internal Medicine, University of Parma) were grown in M199
supplemented with 10% FBS.
For stimulation, TNF-
and LPS (from Escherichia coli,
serotype O55:B5) were added (from 100× stocks in water) to complete growth medium for the times indicated for each experiment. As shown by
cell protein content or endothelial cell population, treatment with the
two compounds produced no significant cell loss up to 48 h.
Amino acid influx.
The experiments were carried out on HUVEC subcultures resulting from
3.5 × 104 cells seeded into 2-cm2 wells
of disposable Falcon 24-well trays (Becton Dickinson Labware Europe, Le
Pont De Claix, France) in 1 ml of growth medium. Cells were employed
after 2-3 days, when cultures were almost confluent (15 ± 2 µg protein/cm2). All the experiments were performed using
the cluster-tray method for the measurement of solute fluxes in
adherent cells (18) with appropriate modifications. Cell
monolayers were washed twice in Earle's balanced salt solution (EBSS)
containing (in mM) 117 NaCl, 26 NaHCO3, 5 KCl, 1.8 CaCl2, 1 NaH2PO4, 0.8 MgSO4, and 5.5 glucose. L-Arginine influx was
assayed with a 30-s incubation of the cells in the same solution
containing L-[14C]arginine. Preliminary
experiments indicated that, in this interval, arginine influx
approached linearity (results not shown). The experiments were
terminated by three rapid washes (<10 s) in ice-cold 0.1 M
MgCl2. Cell monolayers were extracted in 0.2 ml of ethanol, and the radioactivity of extracts was determined with a Wallac Microbeta Trilux. Extracted cell monolayers were then dissolved with
0.5% sodium deoxycholate in 1 M NaOH, and protein content was
determined directly in the well using a modified Lowry procedure, as
previously described (18).
In the experiments in which Na+-independent transport was
to be measured, a modified bicarbonate-free EBSS buffered at pH 7.4 with 20 mM Tris · HCl (NMG-EBSS) was employed. In this
solution, N-methyl-D-glucamine and choline salts
replaced NaCl and NaH2PO4, respectively.
The osmolality of the solutions was routinely checked with a vapor
pressure osmometer (model 5500, Wescor) and found to be 280 ± 10 mosmol/kg.
Expression of influx data.
Amino acid influx is expressed as micromoles per milliliter of
intracellular water per minute. The intracellular fluid volume was
estimated by urea distribution space, as described previously (10), and found to be 6.88 ± 0.84 µl/mg protein.
This value was not significantly changed by the experimental treatments
(results not shown).
Kinetic parameters of arginine influx were determined by nonlinear
regression analysis as follows
|
(1)
|
for a saturable system plus diffusion, where v is the
initial influx, Vmax is the maximal influx,
Km is the Michaelis constant, Kd is the diffusion constant, and [S] is
substrate concentration.
The following equation was employed to describe a competitive-type
inhibition of amino acid transport
|
(2)
|
where v is the initial influx,
v0 is the uptake in the absence of the
inhibitor, Imax is the maximal inhibition, and
[I]0.5 is the inhibitor concentration required for
half-maximal inhibition.
Amino acid efflux.
Arginine efflux was determined by sequentially removing aliquots of the
extracellular medium and replacing them with fresh solution as
described by Rotoli et al. (42) for the efflux of neutral
amino acids. Briefly, cells were loaded with
L-[14C]arginine (5 µCi/ml) for 5 min in
M199, washed twice with EBSS in the presence or absence of NEM (0.5 mM), and incubated in 0.4 ml of the same solution. Escape of
L-[14C]arginine from cells was measured at
10-s intervals up to 1 min, and the amino acid remaining in the cells
was determined after extraction of cell monolayers in 0.2 ml of
ethanol. Data are expressed as percentage of the total arginine
accumulated before the efflux. Initial efflux was calculated from the
derivative at time 0 of the single-exponential function
|
(3)
|
where A is the amount of arginine at time 0, K is the efflux constant, and c is the residual
intracellular amino acid (%/s).
Reverse transcription.
Total RNA from subconfluent cultures of control and TNF-
- or
LPS-stimulated HUVECs, seeded onto 10-cm2 wells, was
isolated with Trizol (Life Technologies, Milan, Italy). RNA (2 µg),
pretreated with RNase-free DNase, heated at 70°C for 10 min, and
placed on ice for 1 min, was then incubated with a mixture containing
0.5 mM dNTPs mix, 25 ng/µl oligo(dT)15-18 (Life
Technologies), 10 mM dithiothreitol, 1× first-strand buffer, 10 units
of RNase inhibitor (Amersham Biotech, Milan, Italy), 200 units of
SuperScript RT (Life Technologies), and water to a final volume of 20 µl for 1 h at 42°C. The reaction was stopped by heating at
70°C for 15 min. The duplex of RNA-DNA was treated with 5 units of
RNase H (US Biochemicals, Cleveland, OH) at 37°C for 20 min, and the
amount of single-strand cDNA was evaluated by fluorometry
(Victor2 1420 Multilabel Counter, Wallac) with the
fluorescent probe Oligreen (Molecular Probes, Eugene, OR) by using
phage M13+ as single-strand DNA standard.
PCR and "semiquantitative PCR."
For PCR, 200 ng of single-strand cDNA from each sample were amplified
in a total volume of 50 µl with 1.25 U of Taq DNA
polymerase (Qiagen, Milan, Italy), 1× PCR buffer, 0.2 mM each dNTPs,
1.5 mM MgCl2, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and proband sense and antisense primers (Table
1) at 0.4 µM each. The primers were
designed according to the known sequences reported in GenBank with the
help of the Primer3 program (42a). The sense primers for the
transporter proteins hCAT2A and hCAT2B recognize different unique
sequences resulting from alternative splicing of the SLC7A2 transcript.
After an initial denaturation at 94°C for 2 min, samples were taken
at 80°C to reduce formation of nonspecific amplification products.
Taq polymerase (1.25 U) was then added, and the reaction
continued with the annealing step at 60°C for 30 s and the
extension step at 72°C for 1 min. Another 33 cycles were carried out,
with the only difference being the 30-s denaturation step. A final
extension of 5 min at 72°C was performed. These conditions were
selected in preliminary experiments to verify that the PCR products
were in the exponential phase of amplification for all the proband and
GAPDH transcripts. Amplified mixtures (10 µl) were electrophoresed
through a 2% agarose gel (NuSieve 3:1-FMC), stained with ethidium
bromide (0.5 µg/ml) in 1× TBE buffer (0.1 M Tris, 90 mM boric acid,
and 1 mM EDTA, pH 8.4), and visualized by ultraviolet light. Product
size was established by comigration with a 100-bp ladder marker
(Bio-Rad Laboratories, Milan, Italy). Pictures of the electrophoresed
cDNAs were recorded with a digital DC 120 Kodak camera and quantified
by ID Image Analysis Software (Kodak Digital Science).
To confirm the identity with the reported human sequences, PCR products
were ligated into pCRII-TOPO vector (TOPO TA cloning, Invitrogen,
Groningen, The Netherlands) and used to transform CaCl2-competent E. coli. Plasmid DNA was
extracted with the Jetquick plasmid miniprep spin kit (Genomed, Bad
Oeynhausen, Germany); sense and antisense strands of the cDNA were
sequenced (MWG Biotech, Ebersberg, Germany).
Northern blot.
For Northern analysis, 15 µg of total RNA per lane were
electrophoresed under denaturing conditions on 1% agarose gel
containing 2.2 M formaldehyde. After staining with ethidium bromide to
document equal sample loading and absence of degradation, RNA was
transferred overnight to positively charged nylon membranes (Zeta
Probe, Bio-Rad Laboratories) and then linked to the membrane by
ultraviolet irradiation with 120 mJ in a Stratalinker UV
cross-linker 1800 (Stratagene, La Jolla, CA). Filters were
prehybridized for 10 min at 42°C and then hybridized overnight at
42°C in 50% formamide, 5% SDS, 4× sodium chloride-sodium
phosphate-EDTA, 20 mM Na2HPO4, and 1×
Denhardt's solution. Blots were washed according to the
manufacturer's instructions and then exposed to Kodak XAR film at
70°C for the appropriate time. Filters were stripped before
rehybridization in boiling 0.1× saline-sodium citrate-0.5% SDS for 10 min. Northern blots were hybridized to 32P-labeled cDNA
probes (Ready-to-Go DNA Labeling Beads, Amersham Pharmacia Biotech)
coding for human GAPDH (gift from Dr. R. Allen, American Red Cross
Laboratories) and for human NOS3 (PCR generated). Densitometric
analysis of the autoradiograms was performed at nonsaturating exposures
with a Molecular Dynamics laser densitometer.
Immunoblotting.
Cells, grown in 10-cm-diameter dishes, were washed twice with ice-cold
PBS, scraped in the same solution, and collected by low-speed
centrifugation. The pellet was suspended in 0.5 ml of lysis buffer
containing 20 mM Tris · HCl (pH 7.4), 1 mM EDTA, 1% Triton, 1 mM Na3VO4, and a cocktail of protease
inhibitors (Sigma, St. Louis, MO). Cell lysate, obtained by brief
sonication (30 s) in an ice-cold bath, was centrifuged at 15,000 g for 20 min at 4°C. Protein concentration of the
supernatant was determined with the Bio-Rad protein assay, with bovine
serum albumin as standard. Sample aliquots of the supernatant,
containing 30 µg of proteins, were employed immediately or stored lyophilized.
Protein samples were suspended in SDS-PAGE sample buffer, boiled at
100°C for 2 min, separated on a 12% SDS-polyacrylamide gel, and
transferred to a polyvinylidene difluoride membrane. The membrane was
blocked in Tris-buffered saline (TBS) containing 1% casein, 0.33%
gelatin, and 1% bovine serum albumin for 2 h at 30°C.
Polyclonal antibody anti-NOS3 (Santa Cruz Biotechnology, Santa Cruz,
CA), diluted 1:300, was added for 1 h at 30°C or overnight at
4°C. After four washes, the membrane was incubated with horseradish peroxidase-coupled anti-rabbit IgG antibody (Amersham Pharmacia Biotech), washed extensively, and developed using enhanced
chemiluminescence (Amersham Pharmacia Biotech).
Nitrite production.
Nitrite formation in the culture media of HUVECs was determined through
a fluorometric approach. The method is based on the production of the
fluorescent molecule 1H-naphthotriazole from 2,3-diaminonaphthalene (DAN) in an acid environment (33).
For the experiment, cells were seeded into 2-cm2 wells of
Falcon 24-well trays in 1 ml of complete growth medium (see Cell
culture). After 2 days, medium was replaced with complete, phenol
red-free medium (0.5 ml/well). TNF-
was added from a 100× stock in
water, and nitrite was determined after 24 and 48 h. For nitrite
determination, 100 µl of medium were put in wells of a black 96-well
plate with a clear bottom (Corning, Cambridge, MA). DAN (20 µl of a
solution of 0.025 mg/ml in 0.31 M HCl) was then added and, after 10 min
at room temperature, the reaction was stopped with 20 µl of 0.7 M
NaOH. Standards were performed in the same medium from a solution of 1 mM sodium nitrite. Fluorescence was determined with a
Victor2 1420 Multilabel Counter.
Statistical analysis.
Statistical analysis of transport and nitrite production data was
performed with analysis of variance, unless otherwise stated. The
comparison between densitometric results of RT-PCR in control and
treated cells was performed with the Wilcoxon test for nonparametric data.
Materials.
FBS was purchased from Euroclone (Milan, Italy) and M199 from Life
Technology. L-[U-14C]arginine (313 mCi/mmol)
was obtained from DuPont de Nemours (Bad-Homburg, Germany), DAN from
Molecular Probes, TNF-
from Alexis (San Diego, CA), and ethanol from
Carlo Erba (Milan, Italy). Sigma was the source of LPS as well as all
other chemicals.
 |
RESULTS |
Characterization of arginine influx in HUVECs.
NEM inhibits selectively system y+ and, thus, can be
employed to discriminate the various mechanisms operating the influx of cationic amino acids (13). To evaluate the effect of NEM
on arginine transport in HUVECs, we performed a preliminary experiment in which the inhibitory effect of NEM, added to the culture medium 5 min before the transport assay at 0.1-2 mM, was assessed in the
presence and absence of Na+ (Fig.
1). Arginine influx in HUVECs was
completely Na+ independent and partially inhibited by NEM.
In the presence and absence of Na+, Imax
accounted for <50% of the initial influx. Preliminary experiments showed that inhibition of arginine influx by NEM was not further enhanced by prolongation of treatment (not shown). HUVEC cultures exhibited morphological alterations and a decrease in protein content
when treated with >0.5 mM NEM (data not shown). For this reason, the
inhibitor was employed at 0.5 mM throughout the study.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
L-Arginine influx (v) in human
umbilical vein endothelial cells (HUVECs): Na+ dependence
and sensitivity to N-ethylmaleimide (NEM). Cell monolayers
maintained in complete growth medium were pretreated for 5 min with
NEM. NEM was added to the incubation medium from a 100× stock solution
in water. Cells were washed twice in Earle's balanced salt solution
(EBSS, ) or in
N-methyl-D-glucamine (NMG)-EBSS
( ), and L-arginine influx was assayed by
30-s incubations in the same solutions supplemented with 100 µM
L-[14C]arginine (1 µCi/ml). Points are means of 4 independent determinations within 1 representative experiment. Error
bars, SD. Experiment was repeated 3 times with similar results. Curves
represent best fit of the data to Eq. 2. Regression
parameters were as follows: inhibitor concentration required for
half-maximal inhibition ([I]0.5) = 0.38 ± 0.13 mM and maximal inhibition (Imax) = 0.059 ± 0.006 µmol · ml cell
water 1 · min 1 and
[I]0.5 = 0.33 ± 0.12 mM and
Imax = 0.078 ± 0.008 µmol · ml cell
water 1 · min 1 in the presence and
absence of Na+, respectively. [NEM], NEM concentration.
|
|
Figure 2 shows the kinetic analysis of
L-arginine transport in HUVECs in the absence and presence
of 0.5 mM NEM. Data in Fig. 2A indicate that, in the absence
of NEM (total influx) and in NEM-treated cells (NEM-resistant influx),
arginine transport can be described by the additive contributions of a
single saturable system and a nonsaturable component, formally
undistinguishable from diffusion in the concentration range adopted.
The Hofstee plot of the saturable components of arginine influx is
shown in Fig. 2B. For this representation, nonsaturable
influx has been subtracted from the NEM-resistant component, while the
NEM-sensitive fraction has been obtained from the difference between
total influx and NEM-resistant arginine influx. Both components are
accounted for by a single system, with a higher affinity of the
NEM-resistant component (Km = 0.031 ± 0.002 vs. 0.102 ± 0.021 mM), while Vmax values were comparable (0.092 ± 0.005 and 0.110 ± 0.017 µmol · ml
1 · min
1 for
NEM-resistant and NEM-sensitive components, respectively).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Kinetic analysis of L-arginine transport in
HUVECs. A: 30-s influx of increasing concentrations of
L-[14C]arginine ([L-Arg],
0.001-0.73 mM, 4 µCi/ml) in cells pretreated with 0.5 mM NEM for
5 min (NEM-resistant influx, ) or in control cells
(total influx, ). Points are means of 3 independent
determinations within 1 representative experiment. Error bars, SD.
Curves represent best fit of data to Eq. 1. B:
Eadie-Hofstee graphical representation of NEM-resistant
( ) and NEM-sensitive ( ) arginine
uptake. NEM-resistant arginine influx is obtained after subtraction of
the nonsaturable component from influx data in A. Data of
NEM-sensitive influx were calculated from the difference between total
and NEM-resistant arginine influx at each indicated concentration of
the amino acid. Lines are best-fit linear regressions.
|
|
To identify the NEM-resistant component, the effects of leucine on
arginine influx were evaluated in the presence or absence of
Na+. The results presented in Fig.
3A indicate that, in
NEM-treated cells, leucine inhibited arginine influx only in the
presence of Na+, with an Imax >80% of the
NEM-resistant arginine influx. Conversely, no significant inhibition of
arginine transport was observed in the absence of Na+.
Leucine inhibition was restricted to the NEM-insensitive
component of arginine influx, because the NEM-sensitive
fraction was not significantly affected by
1 mM
L-leucine (Fig. 3B).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of L-leucine on
L-arginine influx in the presence and absence of
Na+. HUVECs were washed twice in EBSS (filled symbols) or
in NMG-EBSS (open symbols). Arginine influx was determined with 30-s
incubations in the same solutions supplemented with 100 µM
L-[14C]arginine (1 µCi/ml) in the presence
of L-leucine. A: NEM-resistant component. Cells
were pretreated with 0.5 mM NEM during the last 5 min of incubation in
medium 199. Solid line, best fit of experimental data to Eq. 2. Regression parameters for arginine influx determined in the
presence of Na+ were as follows: [I]0.5 = 0.671 ± 0.02 mM and Imax = 0.074 ± 0.008 µmol · ml cell water
1 · min 1. Data are means of 3 independent determinations. Error bars, SD (when greater than size of
symbol). [Leu], leucine concentration. B: NEM-sensitive
component. Data points represent the difference between arginine influx
data (means of 3 independent determinations) in control and NEM-treated
cells at each indicated concentration of leucine.
|
|
These results indicate that in HUVECs the NEM-resistant portion of
arginine influx is mainly due to the activity of system y+L, while the NEM-sensitive, leucine-resistant
fraction can be identified as system y+.
Effect of TNF-
and LPS on the bidirectional fluxes of arginine
in HUVECs.
In the experiment shown in Fig. 4, the
effect of TNF-
and LPS on the discriminated influx of arginine was
studied in HUVECs. For this purpose, cells were maintained in a
complete growth medium in the presence of the two compounds for 3, 6, 9, 12, or 24 h, and arginine influx was determined in NEM-treated
or untreated cells. TNF-
and LPS produced an increase of
L-arginine transport through the sole NEM-sensitive
component, i.e., system y+ (Fig. 4A), while no
significant change was detected for the NEM-resistant component, i.e.,
for system y+L (Fig. 4B). System y+
stimulation required
6 h of treatment and was maximal after 9 h.
At longer times of treatment, the stimulatory effect decreased and
transport activity was not significantly different from untreated control after 24 h of incubation in the presence of TNF-
or
LPS.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
Tumor necrosis factor- (TNF- ) and
lipopolysaccharide (LPS) effect on endothelial pathways for
L-arginine influx. Cells were incubated in the absence
(control) and presence of 10 ng/ml TNF- or 10 µg/ml LPS. After
indicated times, cells were washed twice in EBSS, and
L-arginine influx was assayed with 30-s incubations in the
same solution in the presence of 100 µM
L-[14C]arginine (1 µCi/ml) in untreated
cells (total influx) and in cells pretreated for 5 min with 0.5 mM NEM
(NEM-resistant influx). A: system y+. Data
represent NEM-sensitive arginine influx calculated at each indicated
time as the difference between total and NEM-resistant influx.
B: system y+L. NEM-resistant arginine influx.
Points are means of 4 independent determinations within 1 representative experiment. Error bars, SD. Experiment was repeated 4 times with similar results.
|
|
Table 2 shows the results of a kinetic
analysis of arginine influx through systems y+ and
y+L performed after 9 h of treatment with TNF-
.
Data indicate that the stimulation of system y+ was
accounted for by an increase in Vmax (0.323 vs.
0.130 µmol · ml
1 · min
1
obtained in control cells), while Km was not
significantly modified. As expected, no significant changes of the
kinetic parameters of system y+L were observed. Comparable
results were obtained after LPS treatment (not shown).
To assess the effect of TNF-
on two-way fluxes of arginine, the
efflux of the cationic amino acid was compared in HUVECs treated for
9 h with the cytokine and in control cells (Fig.
5). Total arginine efflux was
significantly faster from cells incubated for 9 h with TNF-
(initial efflux = 1.98 ± 0.05%/s vs. 1.71 ± 0.06%/s,
Fig. 5A). In cells pretreated with NEM, the efflux of the
cationic amino acid was significantly slowed and no effect of TNF-
was detectable (Fig. 5B). TNF-
stimulation of arginine efflux was therefore referable exclusively to a change of the NEM-sensitive component, which corresponds to the outward activity of
system y+ (Fig. 5C), calculated by subtracting
the NEM-resistant component from total efflux.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
Arginine efflux in HUVECs: effect of treatment with TNF- . Cells
were incubated for 9 h in medium 199 in the absence (control) and
presence of TNF- (10 ng/ml). Culture medium (0.33 mM arginine) was
supplemented for 3 min with L-[14C]arginine
(10 µCi/ml, carrier free), and cells were washed in EBSS in the
absence (A) and presence (B) of 0.5 mM NEM and
incubated in 0.4 ml of the same solution. C: NEM-sensitive
component of arginine efflux, calculated by subtraction of data in
B from data in A. Arginine efflux was calculated
as described in MATERIALS AND METHODS. Lines represent best
fit of data to Eq. 3. Data are means of 3 independent
determinations. Error bars, SD (when greater than size of symbol).
|
|
Effects of TNF-
and LPS on the expression of cationic amino acid
transporter genes in HUVECs.
A preliminary analysis of the expression of genes involved in cationic
amino acid transport in HUVECs was performed with RT-PCR. The results
indicated that HUVECs express SLC7A1, which encodes for CAT1, SLC7A2,
which is restricted to the CAT2B transcript, SLC7A6, for the
y+L-related light chain y+LAT2, SLC7A7, for
y+LAT1, and SLC3A2, which encodes for the y+L
heavy chain 4F2hc/CD98.
Figures 6 and
7 report the results of an RT-PCR
analysis of the expression of genes for cationic amino acid
transporters in TNF-
-treated HUVECs. The cytokine caused a decrease
in SLC7A1 expression after 6 h of treatment (Fig. 6A),
whereas a significant increase in CAT2B expression was detected after
3 h of incubation in the presence of TNF-
(Fig. 6B).
The densitometric analysis (Fig. 6C) showed that the
relative density of SLC7A1/CAT1 to GAPDH RT-PCR product remained
constant until 6 h of treatment and then decreased throughout the
rest of the incubation. Conversely, the relative density of
SLC7A2/CAT2B to GAPDH RT-PCR products increased progressively up to
6 h of incubation, remained high up to 12 h, and returned to
basal values at 24 h. The Wilcoxon test with all the RT-PCR
analyses performed on different cell strains revealed a highly
significant increment (P < 0.01) of CAT2B expression at all times of treatment except 24 h and a significant decrease (P < 0.05) of SLC7A1 expression at >9 h of treatment.
Similar experiments performed with LPS yielded comparable results (not shown).

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of TNF- on expression of genes related to
system y+ in HUVECs. Cultures were incubated for the
indicated times in the presence of TNF- (10 ng/ml) before RNA
extraction and reverse transcription. cDNA was employed as template for
PCR coamplification reactions in which glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) primers were employed together with primers for
SLC7A1/CAT1 (A) or SLC7A2/CAT2B (B). After
electrophoresis of RT-PCR products, gels were stained with ethidium
bromide and photographed. C: densitometric analysis of gels
obtained in representative experiments in A and
B. Relative intensity of SLC7A1 and CAT2B amplification
products was normalized to that of the coamplified GAPDH product. The
analysis, repeated twice in 3 different cell strains, yielded
comparable results.
|
|

View larger version (97K):
[in this window]
[in a new window]
|
Fig. 7.
TNF- effect on expression of genes related to system
y+L in HUVECs. Cultures were incubated in the presence of
TNF- (10 ng/ml) before RNA extraction and reverse transcription. DNA
(200 ng) was employed as template for PCR coamplification reactions in
which GAPDH primers were employed together with primers for 4F2hc,
SLC7A6, or SLC7A7. After electrophoresis of RT-PCR products, gels were
stained with ethidium bromide and photographed. Gels were obtained from
a single representative experiment repeated in 3 different cell strains
with comparable results.
|
|
RT-PCR products of the y+L-related genes SLC7A6
(y+LAT2), SLC7A7 (y+LAT1), and SLC3A2 (4F2hc)
did not show any significant variation at any time of treatment with
TNF-
(Fig. 7) or LPS (not shown).
Expression and sensitivity to TNF-
of NOS isozymes in HUVECs.
Figure 8A shows the results of
a representative Northern blot experiment in which the abundance of
NOS3 mRNA was determined during incubation of HUVECs in the presence of
TNF-
(10 ng/ml). A decrease in the expression of NOS3 was detectable
after 3 h of incubation in the presence of the cytokine.
Quantification of the effect, performed through determination of the
ratio of NOS3 to GAPDH (Fig. 8B), indicates that NOS3 mRNA
expression was inhibited by >80% after 24 h of exposure to the
cytokine. Western blot analysis (Fig. 8, C and D)
showed that the decrease in NOS3 protein was less pronounced, with a
decrease of 44% and 40% detected after 24 and 48 h,
respectively, of treatment with TNF-
.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 8.
Nitric oxide synthase type III (NOS3) expression in
HUVECs: effect of TNF- . Endothelial cultures were incubated for
indicated times in the presence of TNF- (10 ng/ml) before RNA
extraction and Northern blot analysis with NOS3 and GAPDH probes
(A). For densitometric analysis (B), relative
intensity of NOS3 mRNA was normalized to that of GAPDH mRNA. Experiment
was repeated twice in 3 different HUVEC strains with comparable
results. C: representative Western blot analysis of NOS3
protein in control HUVECs and in cells incubated for 24 or 48 h in
the presence of TNF- (10 ng/ml). Experiment was repeated 3 times
with comparable results. D: densitometric analysis of
Western blot analysis in C. C, control; AU, arbitrary
unit.
|
|
RT-PCR analysis indicated that no expression of NOS2 was detected in
HUVECs in the absence of TNF-
or in the presence of the cytokine at
10 ng/ml for various times of incubation (Fig. 9). Under the same conditions of
amplification, the expression of NOS2 was readily detected in human
bone marrow stromal cells stimulated for 9 h with the cytokine.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 9.
Lack of nitric oxide synthase type II (NOS2) expression
in HUVECs. Cultures were incubated in the presence of TNF- (10 ng/ml) before RNA extraction, reverse transcription, and
coamplification with NOS2 and GAPDH primers. After electrophoresis of
RT-PCR products, gels were stained with ethidium bromide and
photographed. BMSC, RT-PCR products obtained with bone marrow stromal
cells, incubated for 9 h with TNF- (10 ng/ml), employed as a
positive control. Experiment was repeated twice in 3 different HUVEC
strains with comparable results.
|
|
Effect of TNF-
on nitrite production of HUVECs.
The accumulation of nitrites in the extracellular medium of HUVECs
treated with TNF-
for 24 and 48 h and in control cells was
determined with a fluorometric method (Fig.
10). No significant difference was
detected between TNF-
-treated and control cells at either time.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 10.
Nitrite production ([nitrite]out) in
HUVECs after treatment with TNF- . Cell monolayers, grown in phenol
red-free growth medium, were incubated for 24 or 48 h in the
absence (control) and presence of TNF- (10 ng/ml). Fluorometry was
used to determine nitrite production in the culture medium. Values are
means ± SD of 12 independent determinations in a representative
experiment. Experiment was repeated 3 times with similar results.
|
|
 |
DISCUSSION |
The characterization of endothelial arginine transport in the
present study has demonstrated a thus far overlooked complexity. The
cationic amino acid enters endothelial cells through at least two
high-affinity components. One component corresponds to system y+ and is due to the activities of CAT1 and CAT2B. The
other component corresponds to the leucine-accepting system
y+L and is also due to at least two transporters: the
heterodimers 4F2hc/y+LAT1 and 4F2hc/y+LAT2. The activity of
system y+L has been recently demonstrated in other human
mesenchymal cells (11) where it depends on the expression
of the genes SLC3A2, SLC7A6, and SLC7A7, which also are expressed in
HUVECs. However, at variance with human fibroblasts, where
SLC7A6, encoding for y+LAT2, seems to be predominant
(11), SLC7A7 and SLC7A6 appear to be expressed at
comparable levels in HUVECs. The physiological relevance of the
contributions of systems y+ and y+L to arginine
transport is incompletely understood. Under physiological conditions,
the contribution of system y+ to arginine influx should
prevail, since this system, in contrast to system y+L, is
poorly sensitive to competition by neutral amino acids. In epithelial
models, it is generally accepted that system y+L provides
an efflux route for cationic amino acids in exchange for neutral amino
acids (5, 45). However, the operation of system
y+ also is bidirectional, a characteristic clearly
documented here for endothelial cells.
The overexpression of CAT2B associated with an increase of arginine
transport has been repeatedly observed in endothelial models under
nondiscriminating conditions (7, 15, 23, 28, 38). With the
use of discriminating conditions, it is possible to ascertain that
system y+L activity is not affected by treatment with
TNF-
or LPS and that, consistently, the expression of SLC3A2,
SLC7A7, or SLC7A6 does not exhibit any significant change. Only changes
in the expression of CAT genes, and hence in system y+
activity, underlie the modifications in arginine transport induced by
treatments with TNF-
or LPS. However, the regulatory mechanisms involved appear to be more complex than expected. Indeed, both compounds induce a clear-cut increase in CAT2B expression that foreruns
the stimulation of arginine transport, although, as described for
different examples of regulation of CAT genes (1), the increase in mRNA level appears to be greater than the transport change.
In addition, TNF-
and LPS also affect the level of CAT1 mRNA, which
is significantly decreased at later times of incubation (>9 h). Also
in other cell models, such as macrophages (25, 35) and
smooth muscle cells (19), TNF-
lowers CAT1 expression. In HUVECs, this effect may account for the rapid decline in the stimulation of arginine transport, detected after 12 h of
incubation in the presence of TNF-
or LPS when CAT2B expression
appears to be stimulated. The inability to discriminate between the
activities of the two transporters on operational grounds prevents the
validation of this hypothesis. However, the opposite effects observed
on CAT1 and CAT2B on treatment with TNF-
and LPS suggest different functional roles of the two transporters. Moreover, the different time
courses of the effects point to the involvement of different signals
and/or transduction mechanisms.
In other cell models, high-output NO production is strictly linked to
arginine transport through the coordinated induction of CAT2B and NOS2.
In particular, this phenomenon has been thoroughly characterized in
macrophages (22, 26, 35), vascular smooth muscle cells
(16, 17, 19), and astrocytes (44). The
situation is much less clear in endothelial cells. Under conditions of
acute stimulation of arginine transport (4, 41, 43), an
increased production of NO is observed, although the carrier involved
in these effects has not been identified. On the other hand, it is known that chronic exposure to cytokines or LPS causes an
overexpression of CAT2B and an increase of arginine transport (7,
15, 23, 28, 38), but data on possible consequences in terms of
changes in NO synthesis are contrasting (16, 23). Under
the conditions adopted here, the extracellular concentration of
nitrites did not increase on treatment with TNF-
or LPS,
notwithstanding the clear-cut stimulation of arginine transport.
Although the results presented here do not exclude minor, transient
changes in NO production on treatment of HUVECs with LPS or TNF-
,
they exclude the occurrence of a sustained increase of NO production.
On the other hand, under the same conditions, no basal or induced
expression of NOS2 is detected at the mRNA (Fig. 9) or the protein
level (results not shown). The lack of expression of NOS2 could
possibly be attributed to the lack of interferon-
and interleukin-1,
which have been employed in a recent study for the maximal expression
of NOS2 associated with a high production of nitrites/nitrates in
HUVECs (47). Whatever the reason for lack of NOS2
expression, this report suggests that, in the absence of NOS2
induction, stimulation of arginine transport through CAT2B by TNF-
is not associated with detectable changes in NO production in HUVECs.
Under the conditions employed here, NOS3 is the only source for the
low, basal NO production, which appears unaffected by TNF-
or LPS
treatment (Fig. 10). Because the Km of arginine
for NOS3 is in the micromolar range (40), arginine, the
intracellular concentration of which is in the millimolar range
(3, 9), should not be a limiting factor for NO production.
It is known that NOS3 activity is unaffected even by marked changes in
the intracellular concentration of arginine (9);
therefore, it is hardly surprising that the transient transport change
described here can affect NO production through this NOS isozyme.
Moreover, expression of this NOS isoform in HUVECs has been found to be inhibited by chronic exposure to TNF-
(Fig. 8), an effect consistent with the results obtained in other endothelial cell models (12, 27, 46). A structural association between NOS3 and CAT1 has been
proposed that could imply a "channeling" of transported arginine toward NO synthesis (32). Although the data presented here
do not support this hypothesis directly, they document a parallel decrease in the expression of NOS3 and CAT1, suggesting a coordinated regulation compatible with a functional link between the two proteins.
In nonendothelial cell models, the stimulation of system y+
raises arginine influx and efflux (29). Similar results
obtained here for HUVECs indicate that TNF-
- or LPS-treated
endothelial cells are endowed with an enhanced capability for arginine
extrusion via system y+, suggesting that treatment with
these compounds could promote the transendothelial flux of the cationic
amino acid. In this case, stimulation of arginine transport would
ensure an increased availability of the cationic amino acid to other
cells of the vessel wall, such as smooth muscle cells, in which high
extracellular levels of arginine are required to maintain high-output
NO production through the functional axis CAT2B/NOS2 (17,
19). The validation of this hypothesis will be matter of further investigations.
 |
ACKNOWLEDGEMENTS |
This study was partially supported by Istituto di Ricovero e Cura a
Carattere Scientifico Centro Cardiologico Fondazione Monzino (Milan,
Italy), Consiglio Nazionale delle Ricerche, Target Project "Biotechnology," and Ministero dell' Università e della
Ricerca Scientifica e Tecnologica Progetto di Ricerca di Interesse
Nationale "Coordinated Regulation of NO Production and Arginine Transport."
 |
FOOTNOTES |
Address for reprint requests and other correspondence: V. Dall'Asta, Sezione di Patologia Generale e Clinica, Dipartimento di
Medicina Sperimentale, Università di Parma, Via Volturno, 39, 43100 Parma, Italy (E-mail: valeria.dallasta{at}unipr.it).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 5 July 2001; accepted in final form 4 September 2001.
 |
REFERENCES |
1.
Aulak, KS,
Mishra R,
Zhou L,
Hyatt SL,
de Jonge W,
Lamers W,
Snider M,
and
Hatzoglou M.
Post-transcriptional regulation of the arginine transporter Cat-1 by amino acid availability.
J Biol Chem
274:
30424-30432,
1999[Abstract/Free Full Text].
2.
Beckman, JS,
and
Koppenol WH.
Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly.
Am J Physiol Cell Physiol
271:
C1424-C1437,
1996[Abstract/Free Full Text].
3.
Bogle, RG,
Baydoun AR,
Pearson JD,
and
Mann GE.
Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells.
J Physiol (Lond)
490:
229-241,
1996[Abstract].
4.
Bogle, RG,
Coade SB,
Moncada S,
Pearson JD,
and
Mann GE.
Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells.
Biochem Biophys Res Commun
180:
926-932,
1991[ISI][Medline].
5.
Broer, A,
Wagner CA,
Lang F,
and
Broer S.
The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine.
Biochem J
349:
787-795,
2000[ISI][Medline].
6.
Bussolati, O,
Sala R,
Astorri A,
Rotoli BM,
Dall'Asta V,
and
Gazzola GC.
Characterization of amino acid transport in human endothelial cells.
Am J Physiol Cell Physiol
265:
C1006-C1014,
1993[Abstract/Free Full Text].
7.
Cendan, JC,
Souba WW,
Copeland EM, III,
and
Lind DS.
Cytokines regulate endotoxin stimulation of endothelial cell arginine transport.
Surgery
117:
213-219,
1995[ISI][Medline].
8.
Closs, EI,
Graf P,
Habermeier A,
Cunningham JM,
and
Forstermann U.
Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: three related carriers with distinct transport properties.
Biochemistry
36:
6462-6468,
1997[ISI][Medline].
9.
Closs, EI,
Scheld JS,
Sharafi M,
and
Forstermann U.
Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters.
Mol Pharmacol
57:
68-74,
2000[Abstract/Free Full Text].
10.
Dall'Asta, V,
Bussolati O,
Sala R,
Parolari A,
Alamanni F,
Biglioli P,
and
Gazzola GC.
Amino acids are compatible osmolytes for volume recovery after hypertonic shrinkage in vascular endothelial cells.
Am J Physiol Cell Physiol
276:
C865-C872,
1999[Abstract/Free Full Text].
11.
Dall'Asta, V,
Bussolati O,
Sala R,
Rotoli BM,
Sebastio G,
Sperandeo MP,
Andria G,
and
Gazzola GC.
Arginine transport through system y+L in cultured human fibroblasts: normal phenotype of cells from LPI subjects.
Am J Physiol Cell Physiol
279:
C1829-C1837,
2000[Abstract/Free Full Text].
12.
De Frutos, T,
de Miguel LS,
Garcia-Duran M,
Gonzalez-Fernandez F,
Rodriguez-Feo JA,
Monton M,
Guerra J,
Farre J,
Casado S,
and
Lopez-Farre A.
NO from smooth muscle cells decreases NOS expression in endothelial cells: role of TNF-
.
Am J Physiol Heart Circ Physiol
277:
H1317-H1325,
1999[Abstract/Free Full Text].
13.
Deves, R,
Angelo S,
and
Chavez P.
N-ethylmaleimide discriminates between two lysine transport systems in human erythrocytes.
J Physiol (Lond)
468:
753-766,
1993[Abstract].
14.
Deves, R,
and
Boyd CA.
Transporters for cationic amino acids in animal cells: discovery, structure, and function.
Physiol Rev
78:
487-545,
1998[Abstract/Free Full Text].
15.
Durante, W,
Liao L,
Cheng K,
and
Schafer AI.
Selective induction of a cationic amino acid transporter by tumor necrosis factor-
in vascular endothelium.
Proc Assoc Am Physicians
108:
356-361,
1996[ISI][Medline].
16.
Durante, W,
Liao L,
Iftikhar I,
O'Brien WE,
and
Schafer AI.
Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium.
Circ Res
78:
1075-1082,
1996[Abstract/Free Full Text].
17.
Durante, W,
Liao L,
and
Schafer AI.
Differential regulation of L-arginine transport and inducible NOS in cultured vascular smooth muscle cells.
Am J Physiol Heart Circ Physiol
268:
H1158-H1164,
1995[Abstract/Free Full Text].
18.
Gazzola, GC,
Dall'Asta V,
Franchi-Gazzola R,
and
White MF.
The cluster-tray method for rapid measurement of solute fluxes in adherent cultured cells.
Anal Biochem
115:
368-374,
1981[ISI][Medline].
19.
Gill, DJ,
Low BC,
and
Grigor MR.
Interleukin-1
and tumor necrosis factor-
stimulate the cat-2 gene of the L-arginine transporter in cultured vascular smooth muscle cells.
J Biol Chem
271:
11280-11283,
1996[Abstract/Free Full Text].
21.
Grisham, MB,
Jourd'Heuil D,
and
Wink DA.
Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation.
Am J Physiol Gastrointest Liver Physiol
276:
G315-G321,
1999[Abstract/Free Full Text].
22.
Hammermann, R,
Dreissig MD,
Mossner J,
Fuhrmann M,
Berrino L,
Gothert M,
and
Racke K.
Nuclear factor-
B mediates simultaneous induction of inducible nitric oxide synthase and upregulation of the cationic amino acid transporter CAT-2B in rat alveolar macrophages.
Mol Pharmacol
58:
1294-1302,
2000[Abstract/Free Full Text].
23.
Irie, K,
Tsukahara F,
Fujii E,
Uchida Y,
Yoshioka T,
He WR,
Shitashige M,
Murota S,
and
Muraki T.
Cationic amino acid transporter-2 mRNA induction by tumor necrosis factor-
in vascular endothelial cells.
Eur J Pharmacol
339:
289-293,
1997[ISI][Medline].
24.
Jaffe, EA,
Nachman RL,
Becker CG,
and
Minick CR.
Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.
J Clin Invest
52:
2745-2756,
1973[ISI][Medline].
25.
Kakuda, DK,
Finley KD,
Maruyama M,
and
MacLeod CL.
Stress differentially induces cationic amino acid transporter gene expression.
Biochim Biophys Acta
1414:
75-84,
1998[ISI][Medline].
26.
Kakuda, DK,
Sweet MJ,
MacLeod CL,
Hume DA,
and
Markovich D.
CAT2-mediated L-arginine transport and nitric oxide production in activated macrophages.
Biochem J
340:
549-553,
1999[ISI][Medline].
27.
Lamas, S,
Marsden PA,
Li GK,
Tempst P,
and
Michel T.
Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform.
Proc Natl Acad Sci USA
89:
6348-6352,
1992[Abstract].
28.
Lind, DS,
Copeland EM, III,
and
Souba WW.
Endotoxin stimulates arginine transport in pulmonary artery endothelial cells.
Surgery
114:
199-205,
1993[ISI][Medline].
29.
Low, BC,
and
Grigor MR.
Angiotensin II stimulates system y+ and cationic amino acid transporter gene expression in cultured vascular smooth muscle cells.
J Biol Chem
270:
27577-27583,
1995[Abstract/Free Full Text].
30.
MacLeod, CL,
Finley KD,
and
Kakuda DK.
y+-Type cationic amino acid transport: expression and regulation of the mCAT genes.
J Exp Biol
196:
109-121,
1994[Abstract].
31.
Mann, GE,
Pearson JD,
Sheriff CJ,
and
Toothill VJ.
Expression of amino acid transport systems in cultured human umbilical vein endothelial cells.
J Physiol (Lond)
410:
325-339,
1989[Abstract].
32.
McDonald, KK,
Zharikov S,
Block ER,
and
Kilberg MS.
A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox."
J Biol Chem
272:
31213-31216,
1997[Abstract/Free Full Text].
33.
Misko, TP,
Schilling RJ,
Salvemini D,
Moore WM,
and
Currie MG.
A fluorometric assay for the measurement of nitrite in biological samples.
Anal Biochem
214:
11-16,
1993[ISI][Medline].
34.
Moncada, S,
and
Higgs A.
The L-arginine-nitric oxide pathway.
N Engl J Med
329:
2002-2012,
1993[Free Full Text].
35.
Nicholson, B,
Manner CK,
Kleeman J,
and
MacLeod CL.
Sustained nitric oxide production in macrophages requires the arginine transporter CAT2.
J Biol Chem
276:
15881-15885,
2001[Abstract/Free Full Text].
37.
Palacin, M,
Estevez R,
Bertran J,
and
Zorzano A.
Molecular biology of mammalian plasma membrane amino acid transporters.
Physiol Rev
78:
969-1054,
1998[Abstract/Free Full Text].
38.
Pan, M,
Wasa M,
Lind DS,
Gertler J,
Abbott W,
and
Souba WW.
TNF-stimulated arginine transport by human vascular endothelium requires activation of protein kinase C.
Ann Surg
221:
590-601,
1995[ISI][Medline].
39.
Parolari, A,
Sala R,
Antona C,
Bussolati O,
Alamanni F,
Mezzadri P,
Dall'Asta V,
Gazzola GC,
and
Biglioli P.
Hypertonicity induces injury to cultured human endothelium: attenuation by glutamine.
Ann Thorac Surg
64:
1770-1775,
1997[Abstract/Free Full Text].
40.
Pollock, JS,
Forstermann U,
Mitchell JA,
Warner TD,
Schmidt HH,
Nakane M,
and
Murad F.
Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells.
Proc Natl Acad Sci USA
88:
10480-10484,
1991[Abstract].
41.
Posch, K,
Schmidt K,
and
Graier WF.
Selective stimulation of L-arginine uptake contributes to shear stress-induced formation of nitric oxide.
Life Sci
64:
663-670,
1999[ISI][Medline].
42.
Rotoli, BM,
Bussolati O,
Sironi M,
Cabrini G,
and
Gazzola GC.
CFTR protein is involved in the efflux of neutral amino acids.
Biochem Biophys Res Commun
204:
653-658,
1994[ISI][Medline].
42a.
Rozen S and Skaletsky HJ. Primer3 software distribution (1998).
(http://www-genome.wi.mit.edu/genome_software/other/primer3.html)
43.
Sobrevia, L,
Yudilevich DL,
and
Mann GE.
Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells.
J Physiol (Lond)
499:
135-140,
1997[Abstract].
44.
Stevens, BR,
Kakuda DK,
Yu K,
Waters M,
Vo CB,
and
Raizada MK.
Induced nitric oxide synthesis is dependent on induced alternatively spliced CAT-2 encoding L-arginine transport in brain astrocytes.
J Biol Chem
271:
24017-24022,
1996[Abstract/Free Full Text].
45.
Verrey, F,
Meier C,
Rossier G,
and
Kuhn LC.
Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity.
Pflügers Arch
440:
503-512,
2000[ISI][Medline].
46.
Yoshizumi, M,
Perrella MA,
Burnett JC, Jr,
and
Lee ME.
Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life.
Circ Res
73:
205-209,
1993[Abstract].
47.
Zadeh, MS,
Kolb JP,
Geromin D,
D'Anna R,
Boulmerka A,
Marconi A,
Dugas B,
Marsac C,
and
D'Alessio P.
Regulation of ICAM-1/CD54 expression on human endothelial cells by hydrogen peroxide involves inducible NO synthase.
J Leukoc Biol
67:
327-334,
2000[Abstract].
Am J Physiol Cell Physiol 282(1):C134-C143
0363-6143/02 $5.00
Copyright © 2002 the American Physiological Society